GPT and Hydrocephalus: In the vorasidenib group, 7/24 (29.2%) experienced grade 3 or higher TRAE including brain abscess, tooth infection, aphasia, brain edema, hydrocephalus, alanine aminotransferase (ALT) increase, anemia, hyperglycemia, and hypophosphatemia.